To determine whether, separately or together, streptokinase and aspirin have clinical benefits in acute ischemic stroke similar to those in acute myocardial infarction.
- Aspirin (acute stroke) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Streptokinase (Streptase®)Drug
Intervention Desc: Thrombolytic agent
Randomized, controlled, multi-center, open trial of 622 patients.
CT scan was required prior to randomization. Patients were then randomized with a 2x2 factorial design to either a 1-hour intravenous infusion of 1.5 MU streptokinase, 300 mg/day buffered aspirin for 10 days, both active treatments or neither.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Death or severe disability at 6 months.|